Search

everythinglearnresearchcommunity

for

Search:↓

The secretome from mesenchymal stem cells is a promising treatment that may repair tissue and avoid side effects of stem cell transplantation.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

Topical drugs and near-infrared light therapy show potential for treating alopecia.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Using CRISPR for gene editing in the body is promising but needs better delivery methods to be more efficient and specific.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.

Understanding how hair follicle stem cells work can help find new ways to prevent hair loss and promote hair growth.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.

ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.

Immune cells help regulate hair growth, and better understanding this can improve hair loss treatments.

3-Deoxysappanchalcone helps human hair cells grow and stimulates hair growth in mice by affecting certain cell signaling pathways.

Thyroid diseases may contribute to autoimmune skin diseases, and more research is needed on their relationship.

Some diseases can improve the outcomes of other diseases, leading to new treatment possibilities.

TGPC plus CGT is effective and safe for treating severe alopecia areata in children.

New treatments for hair loss are showing promise due to better understanding of genetics and the immune system.

Simvastatin/ezetimibe did not effectively treat severe alopecia areata and caused side effects in some patients.

Leflunomide and anthralin may effectively treat severe alopecia areata.

Rare changes in the KRT82 gene are linked to a higher risk of Alopecia Areata.

Ruxolitinib treatment may cause eyelash growth.

The document concludes that fexofenadine reduces inflammation in chronic hives, cholestyramine helps half of pregnant women with itchy rashes, and relaxing incisions are a good alternative in facial surgery for the elderly.

Nonsteroid treatments for alopecia areata show promise but need more high-quality research.

Restoring immune privilege in hair follicles could help treat certain types of hair loss.

Oxidative stress may contribute to hair loss in alopecia areata and antioxidants could potentially help as a treatment.

Hydroxychloroquine effectively treated twenty-nail dystrophy in a patient with alopecia areata.